{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:09:39Z","timestamp":1790111379053,"version":"4.0.1"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejpb.2026.115170","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:03:11Z","timestamp":1782601391000},"page":"115170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Buprenorphine long acting injectables: clinical needs, pharmacodynamic and pharmacokinetic basis, and design challenges for solid preformed implants"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9699-4035","authenticated-orcid":false,"given":"Tiandian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj A.","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6694-4501","authenticated-orcid":false,"given":"Rongjin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115170_b0005","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health; 2024. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt47095\/National%20Report\/National%20Report\/2023-nsduh-annual-national.html."},{"key":"10.1016\/j.ejpb.2026.115170_b0010","unstructured":"Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Data Resources: Drug Overdose Deaths\u2014Facts and Statistics (preliminary estimate for 12 months ending Aug 2025). Updated Jan 16, 2026. https:\/\/www.cdc.gov\/overdose-prevention\/about\/index.html."},{"key":"10.1016\/j.ejpb.2026.115170_b0015","unstructured":"CDC. Understanding the Opioid Overdose Epidemic (three-wave framing and dates). https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html."},{"key":"10.1016\/j.ejpb.2026.115170_b0020","unstructured":"CDC. About Overdose Prevention (long-term escalation; synthetic opioids dominate recent overdose deaths; polysubstance trends). https:\/\/www.cdc.gov\/overdose-prevention\/about\/index.html."},{"key":"10.1016\/j.ejpb.2026.115170_b0025","unstructured":"National Institute on Drug Abuse (NIDA). Overdose Death Rates (recent trends including psychostimulant-involved deaths). Updated Aug 21, 2024. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates?."},{"key":"10.1016\/j.ejpb.2026.115170_b0030","unstructured":"NIDA. Medications for Opioid Use Disorder (MOUD effectiveness; treatment framing). Updated Mar 20, 2025. https:\/\/nida.nih.gov\/research-topics\/medications-opioid-use-disorder."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115170_b0035","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YCO.0000000000000717","article-title":"The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis","volume":"34","author":"Ciccarone","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.ejpb.2026.115170_b0040","unstructured":"Hainer R. Polysubstance use and stimulants: a dangerous fourth wave in the opioid crisis. HealthCity. June 13, 2019. Accessed March 24, 2026. https:\/\/healthcity.bmc.org\/polysubstance-use-dangerous-fourth-wave-opioid-crisis\/."},{"key":"10.1016\/j.ejpb.2026.115170_b0045","unstructured":"US Food and Drug Administration. Subutex (BUP) sublingual tablet. Prescribing information. Revised 2021. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020732s024lbl.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0050","unstructured":"US Food and Drug Administration. Suboxone (BUP and naloxone) sublingual tablet. Prescribing information. Revised 2021. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020733s028lbl.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0055","unstructured":"US Food and Drug Administration. Suboxone (BUP and naloxone) sublingual film. Prescribing information. Revised 2010. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/022410s000lbl.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0060","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology review: Suboxone (BUP\/naloxone) sublingual film (NDA 022410, Orig1s000). 2010. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022410Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0065","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology review: Zubsolv (BUP\/naloxone) sublingual tablets (NDA 204242, Orig1s000). 2013. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204242Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0070","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology review: Bunavail (BUP\/naloxone) buccal film (NDA 205637, Orig1s000). 2014. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205637Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0075","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Pharmacology Review: Probuphine (BUP hydrochloride) implant (NDA 204442, Orig1s000). February 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/204442Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0080","unstructured":"US Food and Drug Administration. Sublocade (BUP extended-release) injection, for subcutaneous use, CIII. Prescribing information. Revised February 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209819s031lbl.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0085","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s): Sublocade (BUP extended-release) injection (NDA 209819, Orig1s000). 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209819Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0090","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology review: Cassipa (BUP\/naloxone) sublingual film (NDA 208042, Orig1s000). 2018. Accessed February 18, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208042Orig1s000ClinPharmR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0095","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s): Brixadi (BUP) extended-release injection (NDA 210136, Orig1s000). 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/210136Orig1s000ClinPharmR.pdf."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yrtph.2010.12.007","article-title":"Uniform assessment and ranking of opioid \u03bc receptor binding constants for selected opioid drugs","volume":"59","author":"Volpe","year":"2011","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115170_b0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A Neuropharmacological model to explain BUP induction challenges","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann. Emerg. Med."},{"issue":"9","key":"10.1016\/j.ejpb.2026.115170_b0110","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.156973","article-title":"Modeling BUP reduction of fentanyl-induced respiratory depression","volume":"7","author":"Olofsen","year":"2022","journal-title":"JCI Insight"},{"issue":"22","key":"10.1016\/j.ejpb.2026.115170_b0115","doi-asserted-by":"crossref","first-page":"7341","DOI":"10.1523\/JNEUROSCI.3723-08.2009","article-title":"BUP is a weak partial agonist that inhibits opioid receptor desensitization","volume":"29","author":"Virk","year":"2009","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0120","doi-asserted-by":"crossref","DOI":"10.52965\/001c.37517","article-title":"BUP and its formulations: a comprehensive review","volume":"10","author":"Poliwoda","year":"2022","journal-title":"Health Psychol Res."},{"issue":"7","key":"10.1016\/j.ejpb.2026.115170_b0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2165\/00003088-200544070-00001","article-title":"BUP: clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkader","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000457","article-title":"BUP pharmacology review: update on transmucosal and long-acting formulations","volume":"13","author":"Coe","year":"2019","journal-title":"J. Addict. Med."},{"issue":"10","key":"10.1016\/j.ejpb.2026.115170_b0135","first-page":"668","article-title":"Implantable buprenorphine (Probuphine) for maintenance treatment of opioid use disorder","volume":"97","author":"Goodbar","year":"2018","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.ejpb.2026.115170_b0140","unstructured":"U.S. Food and Drug Administration. NDA 209819 Summary Review (Sublocade [buprenorphine extended-release injection]). Published March 21, 2018. Accessed April 6, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209819Orig1s000SumR.pdf?utm_."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/pharmaceutics14030614","article-title":"Challenges and complications of Poly(lactic-co-glycolic acid)-based long-acting drug product development","volume":"14","author":"Lim","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/10010146","article-title":"Biodegradable polymers for microencapsulation of drugs","volume":"10","author":"Park","year":"2005","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.ejpb.2026.115170_b0155","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/jcph.665","article-title":"Population pharmacokinetic modeling after repeated administrations of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid use disorder","volume":"56","author":"Laffont","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115170_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126006","article-title":"Long-acting injectable buprenorphine PLGA microparticle formulation","volume":"683","author":"Otte","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115170_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2026.114722","article-title":"Compacted solid implant formulations for long-term buprenorphine delivery","volume":"392","author":"Otte","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115170_b0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.msec.2018.11.058","article-title":"In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N\u2011methyl\u20112\u2011pyrrolidone as solvent","volume":"96","author":"Kamali","year":"2019","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.ejpb.2026.115170_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2021.102558","article-title":"Buprenorphine loaded PLGA microparticles: characterization of a sustained-release formulation","volume":"63","author":"Schreiner","year":"2021","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115170_b0180","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/17425241003602259","article-title":"Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems","volume":"7","author":"Fu","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115170_b0185","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jsat.2017.04.017","article-title":"The relationship between diversion-related attitudes and sharing and selling BUP","volume":"78","author":"Kenney","year":"2017","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","article-title":"Abuse and diversion of BUP sublingual tablets and film","volume":"47","author":"Lavonas","year":"2014","journal-title":"J. Subst. Abuse Treat."},{"key":"10.1016\/j.ejpb.2026.115170_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104252","article-title":"Diversion of medications to treat opioid use disorder: qualitative findings from formerly incarcerated adults in Massachusetts","volume":"122","author":"Evans","year":"2023","journal-title":"Int. J. Drug Policy"},{"key":"10.1016\/j.ejpb.2026.115170_b0200","unstructured":"United States Government Accountability Office. Opioid Use Disorder: Treatment and Barriers and Options for Expanding Access. Report No. GAO-20-617. Published August 2020. Accessed January 31, 2026. Available at: https:\/\/www.gao.gov\/products\/gao-20-617."},{"key":"10.1016\/j.ejpb.2026.115170_b0205","unstructured":"BRIXADI REMS (BUP) [Risk Evaluation and Mitigation Strategy]. US Food and Drug Administration; May 23, 2023. Accessed January 31, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/210136Orig1s000REMS.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0210","doi-asserted-by":"crossref","DOI":"10.1177\/21501319241233198","article-title":"Access to MAT: participants' experiences with transportation, non-emergency transportation, and telehealth","volume":"15","author":"Boyd","year":"2024","journal-title":"J. Prim. Care Community Health"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115170_b0215","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23032","article-title":"Comparison of treatment retention of adults with opioid addiction managed with extended-release BUP vs daily sublingual BUP-naloxone at time of release from jail","volume":"4","author":"Lee","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115170_b0220","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1176\/appi.ps.201600056","article-title":"Social stigma toward persons with prescription opioid use disorder: associations with public support for punitive and public health-oriented policies","volume":"68","author":"Kennedy-Hendricks","year":"2017","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.ejpb.2026.115170_b0225","unstructured":"Avalere Health. The Cost of Addiction: Opioid Use Disorder in the United States. Avalere Health; May 2025. Accessed September 13, 2025."},{"key":"10.1016\/j.ejpb.2026.115170_b0230","unstructured":"The White House. The Staggering Cost of the Illicit Opioid Epidemic in the United States. Published March 26, 2025. Accessed September 13, 2025."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115170_b0235","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous BUP depot formulations vs daily sublingual BUP with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115170_b0240","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.17377","article-title":"Extended-release injection vs sublingual BUP for opioid use disorder with fentanyl use: a post hoc analysis of a randomized clinical trial","volume":"7","author":"Nunes","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"10173","key":"10.1016\/j.ejpb.2026.115170_b0245","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly BUP depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ejpb.2026.115170_b0250","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"BUP implants for treatment of opioid dependence: randomized comparison to placebo and sublingual BUP\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0255","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of BUP implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual BUP: a randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115170_b0260","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"BUP dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw. Open."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0265","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous BUP depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejpb.2026.115170_b0270","unstructured":"MyHealth.Alberta.ca. BUP\/naloxone (Suboxone): 2-day home dosing plan. Current as of November 21, 2024. https:\/\/myhealth.alberta.ca\/Health\/pages\/conditions.aspx?Hwid=custom.ab_suboxone_homedosingrapid2day_ac_adult."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115170_b0275","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/add.16600","article-title":"Dose-specific clinical outcomes in patients with opioid use disorder treated with 24\u201332 mg\/day of BUP","volume":"119","author":"D\u2019Agata Mount","year":"2024","journal-title":"Addiction"},{"key":"10.1016\/j.ejpb.2026.115170_b0280","unstructured":"US Food and Drug Administration. BUP Drug Products That Are Administered Transmucosally for the Treatment of Opioid Dependence: Modified Labeling Language for Certain BUP Drug Products\u2014Determination of Public Health Interest. December 26, 2024."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2026.115170_b0285","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijpharm.2011.05.049","article-title":"The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems\u2013a review","volume":"415","author":"Fredenberg","year":"2011","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0290","first-page":"217","article-title":"Kinetic modeling on drug release from controlled drug delivery systems","volume":"67","author":"Dash","year":"2010","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.ejpb.2026.115170_b0295","series-title":"Bioresorbable Polymers and their Composites","article-title":"Modeling of drug release from a bioresorbable polymer matrix system","author":"Yasir","year":"2024"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115170_b0300","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/ph18050631","article-title":"PLGA implants for controlled drug delivery and regenerative medicine: advances, challenges, and clinical potential","volume":"18","author":"Omidian","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"18","key":"10.1016\/j.ejpb.2026.115170_b0305","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/polym16182606","article-title":"Recent applications of PLGA in drug delivery systems","volume":"16","author":"Yang","year":"2024","journal-title":"Polymers"},{"issue":"10","key":"10.1016\/j.ejpb.2026.115170_b0310","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3390\/pharmaceutics17101350","article-title":"Sustained-release intra-articular drug delivery: PLGA systems in clinical context and evolving strategies","volume":"17","author":"Lee","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115170_b0315","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jconrel.2024.11.021","article-title":"In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide)","volume":"377","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115170_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120738","article-title":"Coupling the in vivo performance to the in vitro characterization of PLGA microparticles","volume":"604","author":"Otte","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115170_b0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2019.10.014","article-title":"In vitro-in vivo correlation of parenteral PLGA microspheres: effect of variable burst release","volume":"314","author":"Andhariya","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115170_b0330","unstructured":"U.S. Food and Drug Administration. Summary review for NDA 209819, SUBLOCADE (BUP extended-release) injection. Published November 30, 2017. Accessed April 3, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209819Orig1s000SumR.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0335","unstructured":"U.S. Food and Drug Administration. Administrative correspondence for NDA 210136, BRIXADI (BUP) extended-release injection. Published March 28, 2024. Accessed April 3, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/210136Orig1s000AdminCorres.pdf."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0340","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/pharmaceutics14030614","article-title":"Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development","volume":"14","author":"Lim","year":"2022","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115170_b0345","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s11095-023-03487-z","article-title":"In vitro-in vivo correlation of BUP transdermal systems under normal and elevated skin temperature","volume":"40","author":"Thomas","year":"2023","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115170_b0350","unstructured":"BUP hydrochloride tablet [prescribing information]. DailyMed. Accessed March 24, 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=7830fe02-a2ec-48cf-85ce-3e3f6dadab4e&type=display&utm."},{"issue":"5","key":"10.1016\/j.ejpb.2026.115170_b0355","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1586\/ern.09.26","article-title":"BUP for opioid dependence","volume":"9","author":"Ling","year":"2009","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.ejpb.2026.115170_b0360","unstructured":"United States Pharmacopeia. FAQs: Compliance with the USP-NF. Accessed March 24, 2026. https:\/\/www.usp.org\/frequently-asked-questions\/compliance-usp-nf?utm."},{"key":"10.1016\/j.ejpb.2026.115170_b0365","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Product quality review: BUP and naloxone sublingual film (NDA 208042). 2018. Accessed March 24, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/208042Orig1s000ChemR.pdf."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0370","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jps.2600830204","article-title":"Transdermal delivery of BUP through cadaver skin","volume":"83","author":"Roy","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115170_b0375","unstructured":"Lu JX, Rohit P, et al. Biochemistry, dissolution and solubility. In: StatPearls. StatPearls Publishing; updated 2022. Accessed March 24, 2026."},{"key":"10.1016\/j.ejpb.2026.115170_b0380","unstructured":"A.A. Alagga, V. Gupta, Drug absorption. In: StatPearls. StatPearls Publishing; updated 2024. Accessed March 24, 2026."},{"key":"10.1016\/j.ejpb.2026.115170_b0385","unstructured":"Food and Drug Administration. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro\/In Vivo Correlations. U.S. Department of Health and Human Services; September 1997. Accessed April 7, 2026. https:\/\/www.fda.gov\/media\/70939\/download."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0390","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/71916","article-title":"Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide)","volume":"18","author":"Zhu","year":"2000","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejpb.2026.115170_b0395","article-title":"Enhanced degradation of lactide-co-glycolide polymer with basic nucleophilic drugs","volume":"2015","author":"D'Souza","year":"2015","journal-title":"Adv. Pharm."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0400","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1023\/A:1018876308346","article-title":"The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins","volume":"16","author":"Shenderova","year":"1999","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0405","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpb.2006.06.009","article-title":"Effect of drug type on the degradation rate of PLGA matrices","volume":"64","author":"Siegel","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"13","key":"10.1016\/j.ejpb.2026.115170_b0410","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.3390\/nano15131013","article-title":"Protein adsorption on nano- and microparticles: dependence on morphological and physicochemical properties of particles and effect on particle\u2013cell interactions","volume":"15","author":"Gerasimovich","year":"2025","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejpb.2026.115170_b0415","article-title":"Foreign body reaction to subcutaneous implants","volume":"Vol. 865","author":"Kastellorizios","year":"2015"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0420","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/molecules25020338","article-title":"A liposomal formulation for improving solubility and oral bioavailability of nifedipine","volume":"25","author":"Bi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2026.115170_b0425","unstructured":"DrugBank Online. Nicardipine Hydrochloride. DrugBank. Accessed June 15, 2026. https:\/\/go.drugbank.com\/salts\/DBSALT000499."},{"key":"10.1016\/j.ejpb.2026.115170_b0430","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2019.03.016","article-title":"Polymer degradation induced drug precipitation in PLGA implants - why less is sometimes more","volume":"139","author":"Zlomke","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2026.115170_b0435","article-title":"Release mechanisms of PLGA-based drug delivery systems: a review","volume":"10","author":"Siepmann","year":"2025","journal-title":"Int. J. Pharm. X."},{"issue":"48","key":"10.1016\/j.ejpb.2026.115170_b0440","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.15585\/mmwr.mm7348a2","article-title":"Detection of illegally manufactured fentanyls and carfentanil in drug overdose deaths\u2014United States, 2021\u20132024","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"32","key":"10.1016\/j.ejpb.2026.115170_b0445","doi-asserted-by":"crossref","first-page":"491","DOI":"10.15585\/mmwr.mm7432a1","article-title":"Drug overdose deaths involving stimulants\u2014United States, January 2018\u2013June 2024","volume":"74","author":"Tanz","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"26","key":"10.1016\/j.ejpb.2026.115170_b0450","doi-asserted-by":"crossref","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl\u2013involved overdose deaths with detected xylazine\u2014United States, January 2019\u2013June 2022","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"6","key":"10.1016\/j.ejpb.2026.115170_b0455","doi-asserted-by":"crossref","first-page":"124","DOI":"10.15585\/mmwr.mm7306a2","article-title":"Routes of drug use among drug overdose deaths\u2014United States, 2020\u20132022","volume":"73","author":"Tanz","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115170_b0460","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1046\/j.1360-0443.1998.93454910.x","article-title":"Relationship of plasma BUP and norBUP to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual BUP","volume":"93","author":"Kuhlman","year":"1998","journal-title":"Addiction"},{"key":"10.1016\/j.ejpb.2026.115170_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1052113","article-title":"BUP exposure levels to optimize treatment outcomes in opioid use disorder","volume":"13","author":"Laffont","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0470","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12954-023-00906-7","article-title":"Examining the benefit of a higher maintenance dose of extended-release BUP in opioid-injecting participants treated for opioid use disorder","volume":"20","author":"Greenwald","year":"2023","journal-title":"Harm Reduct. J."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115170_b0475","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.48043","article-title":"Comparison of extended-release BUP doses for treating high-risk opioid use: a randomized clinical trial","volume":"8","author":"Shiwach","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115170_b0480","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of BUP maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.ejpb.2026.115170_b0485","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of BUP weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiat."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0490","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.biopsych.2006.04.043","article-title":"BUP duration of action: \u03bc-opioid receptor availability and pharmacokinetic and behavioral indices","volume":"61","author":"Greenwald","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejpb.2026.115170_b0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.07.035","article-title":"BUP maintenance and \u03bc-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy","volume":"144","author":"Greenwald","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.ejpb.2026.115170_b0500","unstructured":"University of Washington Alcohol & Drug Abuse Institute, NIDA CTN Pacific Northwest Node. Injectable BUP: Getting Started. A Guide for Providers. 2023. https:\/\/adai.uw.edu\/pubs\/pdf\/InjectableBUPGettingStarted.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125684","article-title":"How to sterilize biodegradable polymers? An in-depth characterization of effects of low energy electron beam irradiation (LEEI) and gamma irradiation on the molecular weight of poly(lactide-co-glycolide) films","volume":"678","author":"Krieghoff","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115170_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126006","article-title":"Long-Acting injectable BUP PLGA microparticle formulation","volume":"683","author":"Otte","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2026.115170_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124556","article-title":"Development of poly (lactic-co-glycolic acid) (PLGA) based implants using hot melt extrusion (HME) for sustained release of drugs: the impacts of PLGA's material characteristics","volume":"663","author":"Yang","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0520","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","article-title":"PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application","volume":"28","author":"Su","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2026.115170_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115003","article-title":"Polymeric in situ forming depots for long-acting drug delivery systems","volume":"200","author":"Pandya","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0530","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018025013","article-title":"In situ forming depot as sustained-release drug delivery systems","volume":"36","author":"Kanwar","year":"2019","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"12","key":"10.1016\/j.ejpb.2026.115170_b0535","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/mabi.200600129","article-title":"Biodegradable injectable in situ depot-forming drug delivery systems","volume":"6","author":"Chitkara","year":"2006","journal-title":"Macromol. Biosci."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0540","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/pharmaceutics16010115","article-title":"Burst release from in situ forming PLGA-based implants: 12 effectors and ways of correction","volume":"16","author":"Bakhrushina","year":"2024","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0545","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jconrel.2013.08.024","article-title":"PLGA in situ implants formed by phase inversion: critical physicochemical parameters to modulate drug release","volume":"172","author":"Parent","year":"2013","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.ejpb.2026.115170_b0550","first-page":"330","article-title":"Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride","volume":"19","author":"Koocheki","year":"2011","journal-title":"DARU"},{"key":"10.1016\/j.ejpb.2026.115170_b0555","unstructured":"Q. Zhang, B. Qin, Y. Wang, Q. Li, D. Kozak. Scientific gap analysis of polymeric in situ forming depot products for the development of GDUFA research projects [Internet]. Silver Spring (MD): Food and Drug Administration (US), Office of Generic Drugs; 2022 [cited 2026 Mar 25]. https:\/\/www.fda.gov\/media\/149019\/download."},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0560","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2006.11.001","article-title":"Mechanisms controlling protein release from lipidic implants: effects of PEG addition","volume":"118","author":"Herrmann","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2026.115170_b0565","article-title":"Has PEG-PLGA advantages for the delivery of hydrophobic drugs? Risperidone as an example","volume":"60","author":"De Souza","year":"2020","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"3","key":"10.1016\/j.ejpb.2026.115170_b0570","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00418-008-0469-9","article-title":"MALDI imaging mass spectrometry for direct tissue analysis: a new frontier for molecular histology","volume":"130","author":"Walch","year":"2008","journal-title":"Histochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0575","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/s110100180","article-title":"In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals","volume":"11","author":"Close","year":"2011","journal-title":"Sensors (Basel)"},{"issue":"2","key":"10.1016\/j.ejpb.2026.115170_b0580","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijpharm.2005.07.030","article-title":"Effects of the type of release medium on drug release from PLGA-based microparticles: experiment and theory","volume":"314","author":"Faisant","year":"2006","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2026.115170_b0585","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1021\/acsabm.4c01054","article-title":"Mechanistic model for drug release from PLGA-based biodegradable implants for in vitro release testing: development and validation","volume":"7","author":"Mittapelly","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0590","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/psp4.13054","article-title":"Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models","volume":"13","author":"Valderrama","year":"2024","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115170_b0595","unstructured":"Food and Drug Administration. In Vivo Pharmacokinetic Bioequivalence Studies for Long-Acting Injectable Dosage Forms. Available at: https:\/\/www.fda.gov\/media\/166584\/download. Accessed June 14, 2026."},{"key":"10.1016\/j.ejpb.2026.115170_b0600","unstructured":"Envigo. Hsd Dawley\u00ae SD\u00ae Growth Chart. Published September 2015. Accessed June 14, 2026. https:\/\/insights.envigo.com\/hubfs\/resources\/growth-curves\/sprague-dawley-gc-sept2015.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114857","article-title":"Long-acting PLGA microspheres: advances in excipient and product analysis toward improved product understanding","volume":"198","author":"Wan","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2026.115170_b0610","doi-asserted-by":"crossref","first-page":"14512","DOI":"10.1038\/s41598-021-93785-6","article-title":"Investigating PLGA microparticle swelling behavior reveals an interplay of expansive intermolecular forces","volume":"11","author":"Rapier","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0615","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-9556(25)08299-6","article-title":"Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats","volume":"22","author":"Ohtani","year":"1994","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejpb.2026.115170_b0620","unstructured":"Pacific Northwest Node, NIDA Clinical Trials Network. Injectable Buprenorphine: Getting Started. Updated November 7, 2024. Accessed June 14, 2026. https:\/\/adai.uw.edu\/wordpress\/wp-content\/uploads\/InjectableBuprenorphineGettingStarted.pdf."},{"issue":"4","key":"10.1016\/j.ejpb.2026.115170_b0625","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1208\/s12249-013-0019-1","article-title":"The effect of acid pH modifiers on the release characteristics of weakly basic drug from hydrophilic-lipophilic matrices","volume":"14","author":"Dvo\u0159\u00e1\u010dkov\u00e1","year":"2013","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.ejpb.2026.115170_b0630","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0142-9612(01)00101-6","article-title":"Comparison of the effects of Mg(OH)2 and sucrose on the stability of bovine serum albumin encapsulated in injectable poly(D,L-lactide-co-glycolide) implants","volume":"23","author":"Kang","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejpb.2026.115170_b0635","unstructured":"U.S. Food and Drug Administration. FDA Approves New BUP Treatment Option for Opioid Use Disorder. Published May 23, 2023. Accessed September 27, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-BUP-treatment-option-opioid-use-disorder."},{"key":"10.1016\/j.ejpb.2026.115170_b0640","unstructured":"NIDA. Medications to Treat Opioid Use Disorder (TIP-style report). 2018. https:\/\/nida.nih.gov\/sites\/default\/files\/21349-medications-to-treat-opioid-use-disorder.pdf."},{"key":"10.1016\/j.ejpb.2026.115170_b0645","unstructured":"NIDA. Higher doses of BUP may improve treatment outcomes for people with opioid use disorder. National Institute on Drug Abuse website. September 25, 2024. Accessed December 3, 2025. https:\/\/nida.nih.gov\/news-events\/news-releases\/2024\/09\/higher-doses-of-BUP-may-improve-treatment-outcomes-for-people-with-opioid-use-disorder."},{"key":"10.1016\/j.ejpb.2026.115170_b0650","unstructured":"FDA. Applications Covered by Section 505(b)(2) (Guidance for Industry). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applications-covered-section-505b2."},{"key":"10.1016\/j.ejpb.2026.115170_b0655","unstructured":"Food and Drug Administration. Center for Drug Evaluation and Research. Applications Covered by Section 505(b)(2). US Food and Drug Administration website. Published July 20, 1999. Accessed December 3, 2025. https:\/\/www.fda.gov\/media\/72419\/download."},{"key":"10.1016\/j.ejpb.2026.115170_b0660","unstructured":"FDA. Determining Whether to Submit an ANDA or a 505(b)(2) Application (Guidance for Industry). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/determining-whether-submit-anda-or-505b2-application U.S. Food and Drug Administration."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126001918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:42:40Z","timestamp":1790109760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126001918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":132,"alternative-id":["S0939641126001918"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115170","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Buprenorphine long acting injectables: clinical needs, pharmacodynamic and pharmacokinetic basis, and design challenges for solid preformed implants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115170"}}